Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Completed · Phase 3

Conditions studied: Bacterial Vaginosis

In brief

This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.

Key facts

Study ID

NCT02452866

Run by

Symbiomix Therapeutics

People needed

325

Starts

2015-06-01

Expected to finish

2015-10-01

Last updated by the study team

2021-04-13

Who can join

Age: 12 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Are adult females or postmenarchal adolescent girls ≥ 12 years of age.
• Are in good general health as confirmed by a medical history and physical examination, with no known medical or mental health conditions that, in the Investigator's opinion, may interfere with study participation.
• Have a negative urine pregnancy test result prior to study treatment initiation. In addition, female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator
• Agree to abstain from alcohol for 3 days following study treatment.
• Have a clinical diagnosis of bacterial vaginosis
• Agree not to use vaginal douches or similar products for the duration of the study.

You may not qualify if…

• Are pregnant, lactating, or planning to become pregnant during the study.
• Are menstruating or have vaginal bleeding at the Baseline visit (Day 1).
• Are menopausal as determined by the Investigator
• Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex
• Have active genital lesions, including active Herpes simplex lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator
• Have consumed any alcohol within 12 hours prior to treatment with study medication.
• Have a history of an abnormal Pap smear which required cervical biopsy or cervical cauterization within 3 months of the Baseline visit (Day 1).
• Have any history of cervical carcinoma or other carcinomas of the vagina or vulva.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Jonesboro, Arkansas, United States
• Study site — La Mesa, California, United States
• Study site — San Diego, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Denver, Colorado, United States
• Study site — Groton, Connecticut, United States
• Study site — Clearwater, Florida, United States
• Study site — Leesburg, Florida, United States
• Study site — Miami, Florida, United States
• Study site — North Miami, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — Wellington, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Columbus, Georgia, United States
• Study site — Roswell, Georgia, United States
• Study site — Shawnee Mission, Kansas, United States
• Study site — Baltimore, Maryland, United States
• Study site — Fall River, Massachusetts, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Saginaw, Michigan, United States
• Study site — Plainsboro, New Jersey, United States
• Study site — New Bern, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.